Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label pediatric pegcetacoplan study in paroxysmal nocturnal hemoglobinuria
NL-OMON54475Phase 2Not yet recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Primary endpoints: Pharmacokinetics of pegcetacoplan, Efficacy based on hemoglobin, lactate dehydrogenase, and absolute reticulocyte count and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON54475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54475.